| Assessment Status | Rapid Review Complete |
| HTA ID | 25024 |
| Drug | Semaglutide |
| Brand | Wegovy® |
| Indication | Semaglutide (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) of • ≥30kg/m2 (obesity), or • ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. |
| Assessment Process | |
| Rapid review commissioned | 21/03/2025 |
| Rapid review completed | 14/05/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of semaglutide (Wegovy®) for this indication compared with the current standard of care. |
